Pennsylvania -- (MARKET WIRE) -- November 13, 2006 --
PuriCore Appointment
Andrea Holtzman Drucker named as General Counsel
and Corporate Secretary
Malvern, Pennsylvania, and Stafford, UK, 13 November 2006 -- PuriCore plc
("PuriCore") (London Stock Exchange: PURI), the developer of a novel, safe
technology that mimics the human body's natural anti-microbial, hypochlorous
acid, today announces that the company has appointed attorney Andrea ("Andi")
Holtzman Drucker as Senior Vice President, General Counsel, and Corporate
Secretary effective immediately.
Ms. Drucker joins PuriCore from Novavax, Inc., a publicly traded vaccine
company, where she has been acting General Counsel since December 2005. Ms.
Drucker previously served as interim Associate General Counsel at publicly
listed Auxilium Pharmaceuticals, Inc. At both companies Ms. Drucker was
responsible for commercial transactions focusing on business development, as
well as corporate governance, intellectual property and regulatory matters
associated with the U.S. Food and Drug Administration.
Prior to joining Auxilium, Ms. Drucker spent 17 years at FMC Corporation in a
number of roles including six years as Group Counsel of FMC BioPolymer, a
global performance chemicals business providing ingredients and excipients to
the pharmaceutical industry. A graduate of Cornell University and the
University of Pennsylvania School of Law, Ms. Drucker began her career as an
attorney with the Philadelphia law firm Ballard Spahr Andrews & Ingersoll.
Greg Bosch, the Chief Executive of PuriCore, commented:
"I am delighted that Andi is joining the PuriCore management team. With her
background in life sciences at both large, well-established and smaller
organizations, she brings invaluable experience that will add tremendous value
to PuriCore's current and developing businesses."
FOR FURTHER INFORMATION:
PuriCore plc Tel: +1 (484) 321-2701
Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer
Financial Dynamics Tel: +44 (0) 20 7831 3113
Ben Brewerton
John Gilbert
ABOUT PURICORE PLC
PuriCore is a life sciences company focused on the development and
commercialization of its proprietary technology that mimics the production by
the human body of its natural anti-microbial, hypochlorous acid. Hypochlorous
acid is highly effective at killing pathogens such as bacteria, viruses and
fungi and yet is safe and environmentally friendly. PuriCore's solutions have
applications in a wide range of markets where it is important to control
microbial contamination. These markets include medical device disinfection,
food safety, dental equipment decontamination, environmental remediation,
hospitality, water safety, wound management and other applications intended to
limit the spread of infectious disease, including major global threats such as
Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis A,
H.pylori and Legionella.
PuriCore markets a portfolio of branded systems which produce hypochlorous acid
solutions on-site at a customer's location from water, electricity and common
salt. These solutions are generated at a range of concentrations and at a
nearly neutral pH range similar to the human body. They are effective as soaks,
sprays, mists and in other forms.
PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,
UK.
To receive additional information on the Company, please visit our Web site at
www.puricore.com, which does not form part of this press release.
This information is provided by RNS
The company news service from the London Stock Exchange